Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Fulvestrant 85Letrozole 79Paclitaxel 76pembrolizumab 72Specimen Handling 65Trastuzumab 62Carboplatin 56Magnetic Resonance Spectroscopy 52ribociclib 49Capecitabine 49Anastrozole 48pertuzumab 46palbociclib 45exemestane 40Tamoxifen 40Cyclophosphamide 40abemaciclib 39Biopsy 38trastuzumab deruxtecan 31Docetaxel 30Taxes 27Radiotherapy 27Gemcitabine 25Blood Specimen Collection 25130-nm albumin-bound paclitaxel 24Surveys and Questionnaires 23Standard of Care 22olaparib 21sacituzumab govitecan 20eribulin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
romiplostim × Breast × 90 days × Clear all
NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen

Phase 3 Active not recruiting
145 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡